Skip to main content
. 2020 Sep 10;12(9):2586. doi: 10.3390/cancers12092586

Figure 3.

Figure 3

Combined treatment with the AKT inhibitor MK-2206 and both sunitinib and dasatinib results in synergistic cell growth inhibition. (A,C) MDAH2774 and SKOV3 cells were treated with sunitinib, dasatinib, and MK-2206, either alone or in combination at the indicated concentrations. Cell viability was determined 72 h later. (B,D) CI was calculated using the Chou–Talalay method.